The finding that the anti-malarial drug dihydroartemisinin (DHA), which also has anti-cancer activity [104], binds to and promotes the degradation of human TCTP (fortilin) [74], prompted initial studies to test the use of artemisinin derivatives against TCTP, either alone in gallbladder cancer [97] or in combination therapy against breast cancer [96,105]. This evidence concerns the gene TPT1 and cancer.